Canadian medical cannabis company Aurora Cannabis Inc. and Vectura Fertin Pharma, an innovator in wellness and healthcare, have recently unveiled the latest addition to the market, the Luo CBD lozenge. This groundbreaking product is the first medical cannabis CBD lozenge developed by Vectura Fertin Pharma to be launched in Canada. The strategic move follows the commercial collaboration between Vectura Fertin Pharma's subsidiary Cogent International and Aurora Cannabis, where Cogent is responsible for manufacturing, packaging, and labeling the novel CBG lozenge, which offers a dissolvable format that is easy to dose.
Through this collaboration, Cogent will harness Aurora's patient platform to collect valuable feedback on the CBD lozenge, aiming to validate the product proposition and create real-world patient data for future product development. Aurora CEO Miguel Martin expressed enthusiasm about the new launch, highlighting its significance in their partnership with Vectura Fertin Pharma and their dedication to providing innovative solutions to patients in the Canadian medical cannabis landscape. This strategic milestone reinforces Aurora's position as a frontrunner in the Canadian medical cannabis industry.
Looking ahead, Aurora Cannabis Inc. and Vectura Fertin Pharma remain open to exploring further opportunities for potentially commercializing additional medical cannabis products from Vectura Fertin Pharma in the Canadian market. The companies aim to continue their collaboration and build on the success of the Luo CBD lozenge launch. Notably, Aurora's shares saw positive movement, trading higher at $5.57 per share during the pre-market session on Monday morning, indicating investor optimism surrounding this new partnership and product introduction.